WHO Pharmaceuticals Newsletter 2004, No. 06
(2004; 13 pages) Voir le document au format PDF
Table des matières
Ouvrir ce répertoire et afficher son contenuREGULATORY MATTERS
Fermer ce répertoireSAFETY OF MEDICINES
Afficher le documentCHOLINESTERASE INHIBITORS - Reports of cardiac arrhythmias
Afficher le documentCYCLOOXYGENASE-2 INHIBITORS - Plans to review all medicines in this class
Afficher le documentETHINYLESTRADIOL/CYPROTERONE - Increased risk of thrombosis
Afficher le documentHERBAL MEDICINES - Cardiovascular ADRs reported to Health Canada
Afficher le documentINFLUENZA VIRUS VACCINE - Interactions with drugs
Afficher le documentMEDROXY PROGESTERONE - Effect on bone mineral density
Afficher le documentPAMIDRONATE DISODIUM, ZOLEDRONIC ACID - Spontaneous reports of osteonecrosis of the jaw
Afficher le documentSELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) - ADRAC reviews use in children and adolescents
Afficher le documentTERBINAFINE - Reports of blood dyscrasias
Afficher le documentTRICYCLIC ANTIDEPRESSANTS - Overdose risk
Afficher le documentFEATURE
 

HERBAL MEDICINES - Cardiovascular ADRs reported to Health Canada

Canada. Health Canada has received 16 cardiovascular ADR reports associated with synephrine- or Citrus aurantium (bitter orange)-containing products between 1 January 1998 and 28 February 2004. All cardiovascular adverse drug reactions (ADRs), including cardiac arrest, ventricular fibrillation, tachycardia, transient collapse and blackout, were considered to be serious, and two cases were fatal. In 15 of the 16 cases, the suspect products also contained either caffeine (n = 7) or caffeine with ephedra or ephedrine (8).

Reference:

Canadian Adverse Reaction Newsletter 14, No.4, October 2004.

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013